Clinical calculator summary
FNCLCC Soft Tissue Sarcoma Grade
Clinical calculator summary
FNCLCC Soft Tissue Sarcoma Grade
A three-component histologic grading system using differentiation, mitotic count, and necrosis.
Evidence-based context for fast calculator use
- Purpose:
- Classify soft tissue sarcoma grade to support metastatic-risk assessment and treatment planning.
- Population:
- Patients with adult soft tissue sarcoma with pathology data available.
- Factors:
- Tumor differentiation, Mitotic count, Tumor necrosis, Histologic subtype, Sarcoma specialist pathology review
- Reference:
- Trojani et al., Int J Cancer. 1984.
FNCLCC Grade (Soft Tissue Sarcoma)
Clinical Context & Background
Sum of Differentiation (1-3) + Mitosis (1-3) + Necrosis (0-2).Reference Data
| Total Score | Grade | Biological Behavior |
|---|---|---|
| 2 - 3 | Grade 1 | Low Grade (Well differentiated, slow growth) |
| 4 - 5 | Grade 2 | Intermediate Grade |
| 6 - 8 | Grade 3 | High Grade (Poorly differentiated, aggressive) |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use when pathology data are available for adult soft tissue sarcoma and the question is histologic grade.
- Helpful for referral urgency, staging workup, surgery/radiation/systemic therapy discussion, and clinical trial stratification.
- Use with tumor size, depth, anatomic site, margins, imaging, and histologic subtype rather than as a standalone treatment tool.
How To Interpret
- Total scores 2-3 classify as grade 1, 4-5 as grade 2, and 6-8 as grade 3.
- Higher grade generally reflects more aggressive biology and greater metastatic-risk concern.
- Differentiation, mitotic count, and necrosis should come from representative tissue reviewed by a sarcoma-experienced pathologist when possible.
What To Do Next
- Confirm histologic subtype and whether FNCLCC grading is appropriate for that subtype.
- Integrate the grade with MRI/CT staging, surgical margin planning, radiation oncology review, and sarcoma MDT discussion.
- For bone or metastatic disease questions, move to disease-specific staging or skeletal-risk tools instead of reusing FNCLCC alone.
Limitations
- Do not use as a complete sarcoma stage or as a substitute for expert pathology review.
- Some sarcoma subtypes have distinct grading behavior or are not well served by generic FNCLCC scoring.
- The score does not capture tumor size, depth, site, margins, nodal disease, or distant metastases.
Validated Population
Adult soft tissue sarcoma cases where differentiation, mitotic count, and necrosis can be assigned from pathology.
Example use
A tumor with differentiation score 2, 12 mitoses per 10 HPF, and less than 50% necrosis totals 5, corresponding to FNCLCC grade 2; staging and treatment planning still require site, size, depth, and margin context.
Related Tools
Frequently Asked Questions
Does FNCLCC grade replace sarcoma staging?
No. FNCLCC grade is one component of sarcoma assessment. It should be integrated with size, depth, site, nodal or metastatic disease, margins, histologic subtype, and multidisciplinary review.
Why does tumor necrosis matter in FNCLCC grading?
Necrosis reflects aggressive tumor biology and contributes up to 2 points in the FNCLCC system, increasing the final grade when extensive.
Evidence-based oncology decision support. Verify with clinical guidelines.